We are very pleased to announce that Dr Ana Slipicevic has been appointed as acting CEO of one-carbon therapeutics AB. Ana is joining us from Oncopeptides AB where she has been translational research director and leading a team developing and implementing translational research strategies in the early and late-stage clinical trial pipeline. Dr Ana Slipicevic has previously been leading a research team at Oslo University working on DDR strategies to target cancer.
She will be a great asset to the company!
One-carbon therapeutics AB management at ESMO to discuss the ODIN clinical phase 1/2 trial with potential clinical sites across Europe
One-carbon therapeutics AB is discussing the ODIN trial with several
